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Highlights 
 A predominantly restrictive ventilatory pattern is common in myotonic dystrophy  
 Respiratory dysfunction is associated with alveolar hypoventilation and chronic 
hypercapnia. 
 There is no clear relationship between CTG repeat length and severity of respiratory 
dysfunction. 
 The natural history and time-course of respiratory functional decline is very poorly 
understood. 
 There is significant involvement of central respiratory drive but no established 
mechanism. 
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Take Home Message: 
Systematic review of respiratory dysfunction, alveolar hypoventilation and chronic hypercapnia in 
myotonic dystrophy.  
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Abstract 
Myotonic dystrophy type 1 (DM1) is one of the most common muscular dystrophies 
in adults. This review summarises the current literature regarding the natural history of 
respiratory dysfunction in DM1, the role of central respiratory drive and peripheral 
respiratory muscle involvement and its significance in respiratory function, and investigates 
the relationship between genetics (CTG repeat length) and respiratory dysfunction. The 
review included all articles that reported spirometry on 10 or more myotonic dystrophy 
patients. The final review included 55 articles between 1964 and 2017. The major 
conclusions of this review were (1) confirmation of the current consensus that respiratory 
dysfunction, predominantly a restrictive ventilatory pattern, is common in myotonic 
dystrophy and is associated with alveolar hypoventilation, chronic hypercapnia, and sleep 
disturbance in the form of sleep apnoea and sleep related disordered breathing; (2) 
contrary to commonly held belief, there is no consensus in the literature regarding the 
relationship between CTG repeat length and severity of respiratory dysfunction and a 
relationship has not been established; (3) the natural history and time-course of respiratory 
functional decline is very poorly understood in the current literature; (4) there is a 
consensus that there is a significant involvement of central respiratory drive in this alveolar 
hypoventilation however the current literature does not identify the mechanism for this.  
Introduction 
Myotonic dystrophy type 1 (DM1) is one of the most common muscular dystrophies 
in adults[1]. It is an autosomal dominant condition caused by a trinucleotide cytosine-
thymine-guanine (CTG) repeat expansion in the 3’ region of the DPMK gene on chromosome 
19q13.3[2]. The condition is characterised by progressive muscle weakness and myotonia 
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along with involvement of multiple organ systems including respiratory, cardiac, endocrine, 
ophthalmologic, and the central nervous system [3].  
 
Respiratory dysfunction is the most common cause of death in patients with DM1, 
usually resulting from respiratory failure or aspiration [4]. Symptoms related to respiratory 
dysfunction in DM1 also have a significant negative impact on quality of life [5, 6]. As new 
and exciting treatments for myotonic dystrophy are beginning to emerge, it is becoming 
increasingly important that a clear and accurate natural history of the disease is established, 
allowing clinical trials to accurately measure their success. 
 
Respiratory disease in DM1 has a complex aetiology, combining both peripheral 
respiratory dysfunction (respiratory muscle weakness and myotonia) and central respiratory 
drive dysfunction as well as upper airway muscle dysfunction leading to obstructive sleep 
apnoea and aspiration[7]. This combination of factors leads to alveolar hypoventilation, 
chronic hypercapnia and restrictive lung disease[7-9]. The role of peripheral respiratory 
muscle weakness and central respiratory drive in the pathogenesis of respiratory disease in 
these individuals has been the subject of some debate over the last two decades. There is 
increasing evidence of dysregulation of ventilation at a central level[10], however a 
consensus has yet to be reached. 
 
While there is a well-established consensus that myotonic dystrophy patients often 
develop a restrictive ventilatory pattern, there is no consensus on a number of aspects of 
respiratory involvement in the disease including the role of central respiratory drive, the 
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relationship of CTG repeat length with severity of respiratory dysfunction, and the long-term 
clinical course of respiratory functional decline.  
 
This review aims to summarise the current literature regarding the natural history of 
respiratory dysfunction in DM1, the role of central respiratory drive and peripheral 
respiratory muscle involvement and its significance in respiratory function, and investigate 
the relationship between CTG repeat length and respiratory dysfunction. In addition, this 
review will summarise what research has been published and what gaps in the literature are 
present, as well as attempt to investigate any potential bias in the current literature.  
Method 
Article Selection 
Articles were included in this review if they met all of the following criteria: 
published peer-reviewed journal articles which included ten or more participants diagnosed 
with DM1 who underwent respiratory function testing in the form of spirometry. Articles 
were excluded if they met any of the following criteria: case reports or case series, 
randomised control trials for interventions or treatments, conference proceedings, or 
articles published only in abstract form. 
Foreign language articles (six Japanese, one Spanish, one Portuguese and one 
French) which included an original English abstract were partially included in the review. 
Rather than completely excluding them, what information could be gathered from the 
English language abstract was included. The articles were, however, excluded from the 
quality assessment given the lack of full text article. 
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Literature Search 
The included articles were found using a literature search of the databases PubMed, 
Embase, Cochrane, Web of Science and Scopus. Search included keywords “myotonic 
dystrophy”, “MD1”, or “DM1” and the addition of one of the following keywords: 
“respiratory”, “pulmonary”, “lung”, “RFT”, “respiratory function test”, “pulmonary function 
test”, “spirometry”, “hypercapnia”, “hypoventilation”, “apnoea”, “apnea” or “sleep”. This 
was carried out in November 2017, yielding 1432 results after duplicates were removed (see 
supplementary table 1). The titles and abstracts were then reviewed, with articles failing to 
meet the above criteria removed where possible. A breakdown of the excluded articles 
(case reports, reviews/book chapters, etc) can be seen in figure 1. While some articles 
would have fallen into more than one category, they were recorded in only one based on 
the first confirmed reason for exclusion. Full texts of the remaining articles were then 
obtained to further determine their appropriateness for inclusion. Articles were again 
removed as appropriate. Reference lists of included articles were then reviewed to cross-
check for missing articles. The literature search was carried out by two investigators 
independently and the findings cross-checked to reduce the risk of missed articles. 
 
Data Collection 
Data from each article was then recorded for quantitative analysis. Basic information 
about each article was recorded, including location and year of publication. Methodology 
was then recorded, including number of participants, participants mean age and gender 
distribution, the source of participants for the study (e.g. consecutive patients to a tertiary 
neurology clinic, or tertiary respiratory centre referred for non-invasive ventilation work-
up), and the types of investigations included in the study in addition to respiratory function 
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tests (RFTs) (e.g. arterial blood gas, genetic analysis, polysomnography, etc). Finally, the 
results of the investigation were recorded, including mean values of spirometry and other 
investigations where available, statistical correlations reported by the investigators and 
significant conclusions drawn by respective investigators.  
 
Quality Assessment 
 This systematic review was carried out in accordance with the PRISMA checklist for 
systematic reviews and meta-analyses by two investigators independently[11]. The quality 
of each included English language article was assessed using a critical appraisal tool 
developed by Kmet et al (2004) [12]. This tool has a series of checklist points for different 
aspects of the study. A rating of either 0, 1 or 2 is given to each point. Each article was given 
a score out of the total possible points which was converted into a percentage. Studies 
scoring a value >85% were classified as “strong”, 50-85% classified as “adequate” and <50% 
classified as “poor”. A protocol for this review was registered with PROSPERO (the 
international prospective registry for systematic reviews) on 9th November 2017 [13]. This 
can be accessed at 
http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017081108.
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Results 
Literature Search Results 
Fifty-five articles met the criteria for inclusion in this systematic review, ranging from 1964 
to 2017. The majority were published in English, while five were published in Japanese, one 
in Spanish, one in Portuguese and two in French. France was the most common country of 
publication (n=11), with the United Kingdom second most common (n=8). Forty-two of the 
studies (76%) were prospective observational cross-sectional studies or prospective 
observational longitudinal studies. The other thirteen (24%) were retrospective cohort 
studies.  
 
Quality assessment 
All included English language articles (n=46) were assessed for their quality using the critical 
appraisal tool described by Kmet et al (2004). 45 of 46 articles were classified as “strong” 
quality. Only one article was classified as “adequate”, and none were classified as “poor”. 
Each individual quality assessment score can be seen in table 1.  
 
Participants 
The number of participants included in the studies ranged from 10 to 134, with a median of 
19 participants (mean = 33). Reported mean ages of the participants ranged from 22 to 56. 
Both genders were fairly equally represented. Participants included a majority of males in 
47% (n=26) of the articles. Of the aggregate participants in all articles that reported the 
gender distribution, there were 741 male and 737 female participants. 
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Methodology 
Inclusion criteria for the participants of each study varied greatly. Two studies included all 
known myotonic dystrophy patients in a specified area [5, 37]. The majority of other studies 
recruited patients from a general neurology clinic or similar with no specific inclusion 
criteria based on disease severity [8-10, 15, 22, 29-32, 35, 36, 39, 42, 46, 47, 49-51, 53-56, 
60, 62], while two studies specifically recruited participants with no respiratory 
symptoms[20, 25]. Fourteen studies were recruited from a tertiary respiratory clinic or 
specifically recruited for presence of respiratory dysfunction [28, 30, 33, 34, 41, 43-45, 48, 
52, 57-59, 61]. There was significant variation in the characteristics of each cohort, ranging 
from no respiratory symptoms to patients commencing home non-invasive ventilation (refer 
to table 1). The method of investigation also varied greatly between studies. Inclusion of 
various tests including postural RFTs, Maximal Inspiratory Pressure (MIP)/Maximal 
Expiratory Pressure (MEP), arterial blood gas (ABG) and sleep studies can be seen in table 1.  
 
Respiratory function test results 
Almost all the studies found overall abnormal respiratory function tests in a large 
proportion of their participants. The predominant respiratory function abnormality was a 
restrictive ventilatory pattern. Forced vital capacity (FVC) and vital capacity (VC) were the 
most commonly impaired parameters, while total lung capacity (TLC), residual volume (RV), 
and forced expiratory volume in the first second (FEV1) were also commonly affected. 
Summaries of the main spirometry findings for each article are recorded in table 1. 
Abnormal RFTs were found to be associated with various other factors, including severity of 
muscle disease [6, 9, 49-51], age [32], BMI [9, 59], duration of muscle symptoms [29, 32], 
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hypercapnia [7, 45, 48, 49], pulmonary complications [32], cardiac conduction abnormalities 
[9, 51], CTG repeat length [9, 10, 38], and risk of mortality [51]. 
  
Twenty-six of the included articles measured the MIP and/or MEP of participants. The 
majority found a significantly lower MEP in DM1 patients than MIP [63]. Significant 
statistical relationships were found between MIP or MEP and severity of muscle weakness 
[7], FVC [34, 45, 57] and poor quality of life [6]. Both Kumar et al (2007) and Bianchi et al 
(2014) concluded there was no significant relationship between MIP/MEP and sleep apnoea. 
 
Postural changes in spirometry parameters is one method of measuring diaphragmatic 
weakness. This was measured in six of the included studies. Poussel et al (2014) investigated 
a large cohort of 58 participants and found a significant change in both FVC and FEV1 
between sitting and supine positions. The findings of Matsumoto et al (1990) and Horikawa 
et al (1992) also supported this, while Howard et al (1993) and Finnimore et al (1994) found 
postural change in only 2 and 1 participants respectively. Bogaard et al (1992) found no 
postural change at all. Poussel et al (2014) found that postural change in FEV1 was the only 
significant predictor of daytime hypercapnia. 
 
Arterial blood gases were measured in twenty-eight of the included studies. Eight studies 
found daytime hypercapnia in a significant portion of participants [5, 9, 26, 27, 31, 43, 48, 
51, 54]. Hypercapnia was found to be associated with severity of muscle weakness in three 
studies [7, 9, 51]. While there were conflicting results about the relationship between 
hypercapnia and baseline respiratory function tests, a correlation was found between 
spirometry parameters and hypercapnia in five studies [5, 7, 29, 45, 48]. CTG repeat length 
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was associated with hypercapnia in one study [10] while another study found no 
correlation[52]. There were similarly conflicting findings for postural changes in spirometry 
results; a positive correlation in one study[54] and no correlation in another [23].  
 
Genetic associations 
Ten of the included studies measured the CTG repeat length of the patients [9, 10, 38, 39, 
43, 49, 51-53, 56]. Four of these studies found a correlation between CTG repeat length and 
some aspect of respiratory dysfunction, three studies found no correlation between CTG 
repeat length and any respiratory function parameters, and three studies did not comment 
on the relationship. Numbers of participants in these studies were between 13 and 106 with 
a mean of 58 participants.  
CTG repeat length was found to have an association with VC (% predicted) by two of the 
studies [9, 38]. Kaminsky et al (2011) also found that CTG was an independent risk factor for 
restrictive lung disease (defined as both VC and TLC below 70% predicted)[9]. Poussel et al 
(2015) found a correlation between FVC (% predicted) and CTG repeat length, but no 
correlation between ventilatory response to CO2 and CTG repeat length[10]. Monteiro et al 
(2013) found a relationship between CTG repeat length and SpO2, MEP (% predicted) and 
home NIV requirement, but not with FVC, FEV1 or MIP. Those relationships were also lost in 
multivariate analysis [52]. Three studies specifically reported that no relationship between 
CTG repeat length and respiratory parameters were found[39, 49, 53]. The remaining three 
studies made no comment on any relationship[43, 51, 56]. 
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Progressive changes over time 
Seven of the studies investigated the natural progression of respiratory dysfunction over 
time. Follow up periods ranged from 1 to 10 years. Four studies found clear declines in 
spirometry over time[29, 35, 37, 62], while three studies did not find statistically significant 
changes [46, 52] or did not comment on any change over time[32]. Thil et al (2017) reported 
the annual decline in FVC, FEV1 and TLC of -0.73 (% predicted), -1.07 (% predicted) and -1.15 
(%predicted) respectively[62]. They also reported that annual decline in TLC was faster for 
patients who did not have restrictive lung disease at commencement of the study but 
developed it during the follow up period. They concluded that this may imply a non-linear 
decline in lung function. Both Igo et al (1993) and Dahlbom et al (1999) reported significant 
and gradual decline in VC (% predicted) over time[29, 37]. 
 
Central respiratory drive 
The question of the involvement of central respiratory drive in respiratory disease of DM1 
patients was explored in ten of the studies. Five of them used ventilatory response to CO2 in 
an attempt to demonstrate the central involvement. Gillam et al (1964), were the first to 
investigate in a very small group of 3 patients compared to 3 controls, however found no 
significant difference in ventilatory response to CO2. Clague et al (1993) also found no 
significant difference in ventilatory response to CO2 between DM1 patients and controls. 
Bogaard et al (1992) and Poussel et al (2015) all found a significant reduction in ventilatory 
response to CO2 independent of spirometry results, implying a central cause for CO2 
insensitivity. The findings of Zifko et al (1996), Begin et al (1997) and Cho et al (2016) also 
supported some degree of central involvement. In contrast, Begin et al (1980) concluded 
that chemosensitivity in DM1 is preserved and that the impaired response to CO2 is likely a 
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result of muscle weakness only. Serisier et al (1982) were also reserved in their conclusions, 
stating that while their evidence appeared to point to ventilatory response to CO2 being a 
result of peripheral muscle weakness, they could not rule out defective central respiratory 
control.  
 
Sleep disorders and respiratory dysfunction 
Twelve studies investigated the relationship between sleep and respiratory dysfunction 
using overnight sleep studies. The majority found a significant proportion of sleep apnoea, 
sleep disordered breathing or significant overnight oxygen desaturations in DM1 
patients[16, 23, 26, 31, 33, 41, 45, 48, 52, 53]. The apnoeas observed were both obstructive 
and central in origin. There were mixed findings when looking at any statistical relationship 
between daytime respiratory function and sleep abnormalities. Leygonie et al (1977) and 
Kiyan et al (2010) found an association between abnormal sleep and restrictive lung disease 
and daytime hypoxaemia, respectively. Finnimore et al (1994) found only BMI to be 
significantly predictive of sleep abnormalities, with no relationship between sleep and 
daytime RFTs nor PaCO2 observed. Ververs et al (1996) also found no relationship between 
daytime respiratory parameters and sleep disordered breathing.  
Discussion 
This review has identified a large base of literature describing the respiratory dysfunction 
associated with myotonic dystrophy. The aims of this review were to summarise the current 
literature regarding the natural history of DM1, to investigate whether there is a consensus 
in the current literature regarding the question of central versus peripheral origin of 
respiratory dysfunction in DM1, summarise the current literature regarding genetic 
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correlations with respiratory disease severity, and finally to identify gaps in the current 
literature to guide future direction of research. 
 
Summary of Current Literature 
The predominant finding of the majority of the publications was a strong prevalence of 
restrictive lung disease in DM1 patients. FVC, FEV1 and TLC were all commonly impaired to 
varying degrees. Restrictive lung disease is a common result of many types of 
neuromuscular disease, and this consensus in DM1 is not surprising [64, 65]. Both MEP and 
MIP were found to be consistently impaired (MEP often reportedly more severely affected 
than MIP). Respiratory function was also commonly found to be further impaired in the 
supine position compared to sitting. These findings both indicate the presence of significant 
respiratory muscle weakness in DM1 patients[66]. This finding is consistent with the findings 
in other neuromuscular diseases, including Duchenne’s muscular dystrophy (DMD) and 
amyotrophic lateral sclerosis (ALS) [55, 67]. These findings show that the respiratory disease 
in DM1 can, at least partly, be directly attributed to weakness of respiratory muscles.  
 
Progression of respiratory dysfunction over time is an important part of the characterisation 
of the disease, especially as new treatments are finally emerging. A clear natural history of 
respiratory dysfunction in DM1 will aid in clinic trials in the near future. Only 6 studies 
investigated change in respiratory function with time. The largest and most comprehensive 
study was published by Thil et al (2017), reporting annual declines in all respiratory function 
parameters over a follow up period of 5 years. Dahlbom et al (1999) and Igo et al (1993) also 
had similar findings, albeit through less comprehensive study designs. While Terzi et al 
(2008) and Monteiro et al (2013) both found no significant change over time, the follow-up 
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period was limited to 1 year for both, hence these studies are likely to be too short to detect 
any meaningful changes. While the majority of studies indicate a progressive decline in 
respiratory function over time, the trajectory of decline (e.g. linear or non-linear) remains 
unclear. Thil et al suggested that the course may be non-linear, based on their finding that 
the rate of decline varied between groups of patients. When they separated the groups into 
participants with restrictive disease at commencement, participants who developed 
restrictive disease during the follow-up period, and participants who never developed 
restrictive disease, they found that the second group had a significantly higher rate of 
decline. While this implies that there may be a point in the disease progression that the 
respiratory dysfunction deteriorates rapidly, further investigation is needed to confirm this. 
 
Since the discovery of the CTG repeat expansion as the basis of myotonic dystrophy, the 
length of the CTG repeat has been found to be associated with severity of disease. There 
has been shown to be a clear association between CTG repeat length and muscle weakness 
[68]. It appears there is also a clear relationship with cardiac involvement[69]. The 
relationship between CTG repeat length and respiratory dysfunction has not been so clearly 
demonstrated. Of the ten studies that measured CTG repeat length, only 4 showed a clear 
relationship with respiratory dysfunction. Two studies with large participant numbers, 
Kaminsky et al (2011) and Poussel et al (2015), both showed a correlation with restrictive 
ventilatory patterns on spirometry. Neither study, however, reported a multivariate 
statistical analysis. Monteiro et al (2013) found a relationship with SpO2, MEP and 
requirement for home NIV therapy, however these relationships were lost in multivariate 
analysis. Marchini et al (2000) and Bianchi et al (2014) all reported no relationship between 
respiratory dysfunction and CTG repeat length. The latter study had a large sample 
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population of 71, and both studies were specifically investigating clinical correlates of CTG 
repeat length in multiple organ systems. Pruna et al (2011) also concluded no relationship, 
however the study was designed to investigate a new muscular involvement rating system 
rather than specifically CTG repeat length clinical correlations and interpretation was limited 
by the original French language of the article. While there is no consensus in the current 
literature regarding the relationship between CTG repeat length and respiratory 
dysfunction, the studies have been largely underpowered. Given the strong correlation of 
CTG repeat length with other aspects of the disease, a large scale study is needed to assess 
for any potential association. Further investigation is required in this area to further 
elucidate the details of this relationship.  
 
Myotonic dystrophy is known to be associated with hypercapnia, as well as symptoms of 
daytime sleepiness, irregular breathing patterns and other indicators of alveolar 
hypoventilation [70, 71]. These abnormalities appear to be independent of both respiratory 
muscle weakness and sleep disturbance, leading to the suggestion that there is involvement 
of the respiratory centre in the brain stem or another abnormality of central respiratory 
drive. While multiple studies have suggested this, there is still neither a consensus nor a 
proven mechanism. A common method of attempting to differentiate the cause of alveolar 
hypoventilation from respiratory muscle weakness was to assess ventilatory response to 
CO2. By showing that an impaired response to CO2 is independent of respiratory muscle 
involvement, it can be implied that there must be an abnormality in the central respiratory 
drive. While initial investigations by Gillam et al (1964) and Begin et al (1980) suggested that 
the findings could be explained by respiratory muscle weakness alone, both conclusions 
were based on very small sample sizes and were performed solely on participants without 
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any clinical respiratory symptoms or daytime hypercapnia.  Since then, multiple studies 
have found that DM1 patients have an impaired ventilatory response to CO2 which is 
independent of respiratory muscle weakness or restrictive lung disease. The largest study 
investigating this question was carried out by Poussel et al (2015), finding significant 
impairment in ventilatory response to CO2 which was independent of respiratory muscle 
weakness in a large group of 58 DM1 patients of variable disease severity. The consensus 
among the majority of articles assessed indicates alveolar hypoventilation as a central cause 
of respiratory dysfunction in DM1, though the phenomenology is not fully explained by 
peripheral respiratory muscle involvement. An alternative theory was suggested by Serisier 
et al (1982) that the abnormalities of respiratory control may be a result of abnormal 
afferent signalling by the respiratory muscles. Further investigation into the mechanism of 
the central respiratory drive involvement in alveolar hypoventilation is required.  
 
There is a significant body of literature investigating sleep disorders in myotonic dystrophy. 
This review did not specifically include all of this literature, however twelve of the included 
studies did investigate the relationship between sleep and respiratory dysfunction. Results 
were mixed, with several studies finding a correlation between abnormal respiratory 
function tests or restrictive lung disease and abnormal sleep studies. It is likely that 
respiratory sleep abnormalities in DM1 are multifactorial, and while respiratory muscle 
weakness may play a role, central respiratory drive and upper airway obstruction are likely 
to be involved [72-74]. A comprehensive conclusion on sleep abnormalities is beyond the 
scope of this review.  
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ABG was measured in a significant number of the studies, usually measured at rest during 
the daytime. Unsurprisingly, a significant portion of participants were found to be 
hypercapnic at rest. This is consistent with restrictive lung disease commonly described in 
DM1, as well as the prevalence of sleep apnoea and sleep disordered breathing [73-75]. The 
aetiology of the hypercapnia is likely a complex combination of respiratory muscle 
weakness, abnormalities in central respiratory drive and sleep disordered breathing.  
 
Significance in Clinical Practice 
Three important aspects of the clinical management of respiratory disease in DM1 patients 
are screening for respiratory disease at time of initial assessment, predicting progression of 
disease and monitoring the progression of respiratory dysfunction over time. Each of these 
require different tools and biomarkers for assessment. At the time of initial assessment in 
patients with a new diagnosis of DM1, early screening for respiratory disease is crucial. This 
assessment can be based on both symptoms and early investigations. In 2014, the 207th 
ENMC Workshop on chronic respiratory insufficiency in myotonic dystrophies outlined a 
recommendation for initial evaluation of pulmonary function in DM1 patients [76]. The first 
part of recommended screening is a comprehensive review of symptoms of respiratory 
disease. These include, but are not limited to, orthopnoea, dyspnoea on exertion, sleep 
disturbance, morning headaches, apnoeas, decreased cognitive performance, excessive 
daytime sleepiness, fatigue and history of chest infections. In addition to symptom 
screening, the initial assessment was recommended to include spirometry (including FVC 
and FEV1), overnight oximetry and peak cough expiratory flow (PCEF). Additionally, 
maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP) and arterial 
blood gas testing should ideally be performed as well. The aim of these investigations is to 
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identify key aspects of respiratory dysfunction in these patients, including respiratory 
muscle weakness, restrictive lung disease and chronic hypercapnia. Many of these 
biomarkers, including spirometry and PCEF, can be tested in the outpatient clinic setting 
making them ideal and convenient tools for assessment.  
 
Respiratory disease progression in DM1 can be monitored with a similar approach, 
combining symptom screening, respiratory function testing and other investigations. Central 
to management of respiratory disease in DM1 is the introduction of non-invasive ventilation 
(NIV) and identifying the point at which to commence NIV is central to monitoring disease 
progression in these patients. The slow progression of respiratory function, over years to 
decades, creates difficulties in identifying the decline in function early as well as the 
identifying the appropriate time to initiate NIV. The 207th ENMC workshop recommended 
commencement of NIV therapy when symptomatic chronic respiratory insufficiency is 
combined with daytime hypercapnia (PaCO2>50mmHg), FVC <50% predicted plus MIP 
<60cmH2O over 3 measurements, or evidence of nocturnal hypoventilation (including a rise 
in PaCO2 of >8mmHg between evening and morning ABG or overnight oximetry 
demonstrating significant hypoxia). The emergence of symptoms of sleep disordered 
breathing, including sleep disturbance, daytime hypersomnolence and fatigue, should 
prompt overnight polysomnography to assess for obstructive sleep apnoea or sleep 
hypoventilation. 
 
Predicting progression of disease has generally been based on the assessments discussed 
above combined with the CTG repeat length, allowing clinicians to give patients some idea 
of what to expect for the future. The findings of this review highlight the difficulties in the 
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use of CTG repeat length in the clinical setting. While an understanding of the relationship 
between genetics and disease severity is important, its relevance to an individual patient in 
the clinical setting is not so clear. At a population level there is a broad correlation between 
CTG repeat length and disease severity, and as discussed in this review, a large-scale study 
would likely confirm a correlation with respiratory dysfunction. On an individual level, the 
relevance is not so clear, with marked discrepancies between genetics and clinical severity 
commonly seen in clinical practice. A recent Scottish study of DM1 patients revealed several 
patients with large interruptions in their CTG repeat length associated with a milder form of 
the disease [77]. This study concluded that disease severity is related to at least two 
properties, length of the CTG repeat plus the instability of the length (which can be affected 
by a number of factors, including interruptions in the repeat). Further investigation into this 
is required. It is important to keep in mind the limitations of CTG repeat length as a 
prognostic indicator in the clinical setting for an individual patient.  
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Future Research Directions 
This systematic review has identified several areas where further research is required. 
Progression of respiratory dysfunction over time and the natural history of this aspect of the 
disease is an area significantly lacking in the current body of literature. This will become 
crucial as new treatments reach the final stages of clinical trials. An accurate assessment of 
the effect of any new treatments cannot be completed without an accurate and complete 
understanding of the normal progression of the disease. Only six studies have reported 
progression of respiratory dysfunction over time, only one in significant detail, and the 
findings were not all consistent with each other. Additionally, the relationship between CTG 
repeat length and respiratory dysfunction has not yet been shown conclusively. This is vital 
for management planning and prognostic information for the patient. Large studies have 
found inconsistent and contradictory results, and a consensus on the relationship between 
genetics and respiratory dysfunction is yet to be reached. Finally, the question of what (if 
any) involvement the central respiratory drive has on alveolar hypoventilation in myotonic 
dystrophy has not yet been answered. While this review has shown that the majority of 
recent, large investigations found that central respiratory drive is at least a significant 
contributor to alveolar hypoventilation, the mechanism for this is still largely unknown.  
 
Quality Assessment and Potential Biases 
While this systematic review reports a significant body of research into respiratory 
dysfunction in myotonic dystrophy, there are some significant limitations to the findings. 
Many of the investigations had very small numbers of participants (commonly between 10 
and 20), so the conclusions we can draw from each is limited. Additionally, the source of 
participants and level of both muscle weakness and respiratory dysfunction in each cohort 
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was highly variable between studies, ranging from studies comprising asymptomatic young 
healthy patients to studies which specifically included participants commencing home non-
invasive ventilation. While this provides a wide range of results, the generalisability of each 
investigation is difficult to assess. Without large studies involving all levels of disease 
severity, it is difficult to make accurate conclusions. The majority of articles were cross-
sectional studies, which provides some good insight into disease at a specific point but does 
have many limitations as a research design. These include inability to differentiate causation 
from correlation, difficulty accounting for compounding factors, and the inherent difficulties 
with interpreting data at an aggregate level. 
 
Quality assessment of the articles produced overall good scores, however there were 
common downfalls present in almost all articles. Confounding factors were often not 
adequately controlled when making conclusions regarding clinical correlations. This is 
important in a condition such as DM1, where the multisystem involvement means outcomes 
are often multifactorial in aetiology. Additionally, the selection process for participants was 
often not reported, and the method of arriving at the final number of participants unknown 
to the reader. Generally, however, the overall quality of the included articles was 
acceptable.  
 
Justification and Limitations 
The inclusion criteria were developed to account for a number of factors. Articles published 
in a journal, as opposed to conference presentations and abstract-only publications, have 
undergone full peer-review assessment by the appropriate discipline prior to publication, 
ensuring the methodology and conclusions are of a high standard. Including all articles that 
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performed spirometry on participants was intended to allow the review to identify all 
publications that investigated respiratory function while still allowing for comparison with a 
wide array of other factors relevant to respiratory disease (e.g. ABGs, sleep studies, etc). 
Limiting the inclusion criteria to studies with ten or more participants was chosen primarily 
because this review is limited to discussing the conclusion of each article rather than any 
meta-analysis. The authors felt that studies with any less than ten participants would make 
it difficult to make judgement on the conclusions made. While the authors acknowledge 
that in a rarer disease such as myotonic dystrophy many studies are conducted on a small 
number of patients, the limit of 10 participants was felt an appropriate compromise. 
 
Articles published in languages other than English were included in a partial capacity in the 
review. While it is not ideal to assess the article without a full original translation from the 
authors, it was decided that the basic conclusions made by each article should be included 
in this review as they contribute significantly to the current body of literature. All the 
articles included an abstract in English written by the original authors for publication, which 
allowed for some degree of confidence in the interpretation of their conclusions.  
 
This review does have some limitations. The chosen inclusion criteria, in particular to 
include only studies that measured respiratory function using spirometry, did exclude some 
studies that have contributed to the body of literature for respiratory dysfunction in 
myotonic dystrophy. Studies that only assessed pattern of breathing at rest, for example, 
were not included in this systematic review. The inclusion of only articles reporting 
spirometry was also the reason for this review not examining in further detail the role of 
non-invasive ventilation in these patients. Although this is an important part of 
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management in these patients, this review was limited to examining the severity of 
respiratory dysfunction and its associations in observational studies rather than assessment 
of the effectiveness of intervention options. A separate review with a focus on the current 
evidence of NIV in these patients would be useful to collate the current literature. 
Additionally, while the sample of fifty-five articles was fairly large, each article was limited in 
its scope. As a result, the conclusions drawn by this review on some aspects of disease were 
based on much smaller sample sizes. The data reported in this review had a significant 
degree of heterogeneity. Studies varied significantly in sample size, study design and patient 
characteristics. Due to this heterogeneity of the articles included in this review, a 
breakdown of patients into further categories of severity (e.g. congenital, childhood, 
juvenile, adult and late-onset) was not possible. While this is a result of a relatively small 
body of literature and the difficulties of conducting studies in rarer diseases, some degree of 
caution should be taken in the results. Finally, this review was limited to discussing the 
conclusions and findings of each article, without aggregation or meta-analysis of the data. A 
meta-analysis of the available data would be valuable in further expanding on the 
conclusions of this review. 
Conclusion 
The major conclusions of this systematic review into respiratory dysfunction in myotonic 
dystrophy are; (1) confirmation of the current consensus that respiratory dysfunction, 
predominantly a restrictive ventilatory pattern, is common in myotonic dystrophy and is 
associated with alveolar hypoventilation, chronic hypercapnia, and sleep disturbance in the 
form of sleep apnoea and sleep related disordered breathing; (2) contrary to commonly 
held belief, there is no consensus in the literature regarding the relationship between CTG 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Respiratory Dysfunction in Myotonic Dystrophy: Systematic Review 25 
repeat length and severity of respiratory dysfunction and a relationship has not been 
established; (3) the natural history and time-course of respiratory functional decline is very 
poorly understood in the current literature; (4) there is a consensus that there is a 
significant involvement of central respiratory drive in this alveolar hypoventilation however 
the current literature does not identify the mechanism for this. 
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Table 1. Summary of articles included in the review 
Reference Design 
No. of 
Partic-
ipants 
Source of Participants / 
Inclusion criteria 
Summary of Respiratory Function Test 
Results 
Other inclusions in the method Quality 
Score 
[12] 
Quality 
Assess-
ment 
MIP/ 
MEP 
ABG 
Sleep 
Study 
Muscle 
Weakness 
CTG 
length 
Gillam et 
al, 1964 
[14] 
PCS 10 
Unreported/ 
Variable disease severity 
3 of 10 participants had abnormal VC yes - - - - 19 Strong 
Lee et al, 
1964 [15] 
PCS 19 
General neurology 
clinic/ 
Variable disease severity 
17 of 19 participants had abnormal RFTs, VC 
and TLC were the most commonly affected 
parameters. 
- - - - - 19 Strong 
Leygonie 
et al, 1977 
[16] 
PCS 15 
Unreported/ 
Variable disease severity 
9 of 10 participants had RFTs with restrictive 
pattern 
- yes yes - - - - 
Begin et 
al, 1980 
[17] 
PCS 12 
Unreported/ 
Healthy, young 
participants (ages 11-
26) 
Chemosensitivity is well preserved in DM1, 
impaired response to hypercapnia is likely 
due to impaired respiratory muscles, rather 
than a central chemoreceptor abnormality 
- - - - - 20 Strong 
Griggs et 
al 1981 
[18] 
PCS 10 
Unreported/ 
Variable disease severity 
5 of 10 participants had FVC <80% predicted yes - - - - 19 Strong 
Begin et 
al, 1982 
[19] 
PCS 10 
Unreported/ 
Variable disease severity 
Ventilatory output was altered 
predominantly by weakness and fatiguability 
of the respiratory muscles 
- - - - - 20 Strong 
Serisier et 
al, 1982 
[20] 
PCS 19 
General neurology 
clinic/ 
Known respiratory 
disease excluded 
Significant respiratory muscle weakness was 
found in almost all the patients and was 
often present without significant muscle 
impairment.  Impaired ventilatory response 
to CO2 was present in the cohort, but cause 
was unclear (could not rule out central 
respiratory drive abnormality) 
yes - - - - 20 Strong 
Begin et 
al, 1983 
[21] 
PCS 11 
Unreported/ 
Variable disease severity 
Mean FVC 82% predicted. 
Fatigue of the respiratory muscles can be 
readily induced during maximal ventilatory 
output or when oxygen delivery is reduced 
- - - - - 20 Strong 
Jammes 
et al, 1985 
[22] 
PCS 10 
Gen.  neurol. Clinic / No 
history of resp-iratory 
disease /symptoms 
6 of 10 with abnormal VC%, TLC, and 
hypoxaemia 
yes yes - - - 19 Strong 
Matsumot
o H, et al, 
1990 [23] 
PCS 12 
Unreported/ 
Patients with no known 
respiratory disease 
Significantly impaired VC% in both sitting 
and supine position. Mean VC% was 64% in 
sitting position and 55% in supine. 
- yes yes - - - - 
Bogaard 
JM et al, 
1992 [24] 
PCS 17 
Unreported/ 
Variable disease severity 
DM1 participants had sig-nificantly impaired 
overall spirometry compared to controls, 
even in early stage of disease. 
Impairment was in a restrictive lung disease 
pattern. 10 of 17 had FVC <80% 
- yes - - - 20 Strong 
Horikawa 
et al, 1992 
[25] 
PCS 11 
Unreported/ 
No history of respiratory 
disease/symptoms 
Overall reduced FRC in DM1, more reduced 
in supine position than sitting. 
- yes - - - - - 
Yoneyama 
et al, 1992 
PCS 15 
Unreported/ 
Variable disease severity 
RFTs not reported - yes yes - - - - 
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[26] 
Rimmer et 
al, 1993 
[27] 
PCS 11 
Unreported/ 
Variable disease severity 
3 of 11 had mildly impaired FVC % predicted. 
Myotonia of the respiratory muscles was 
inducible with large voluntary breathing 
- Yes - - - 19 Strong 
Howard et 
al, 1993 
[28] 
ROCS 13 
Tertiary respiratory 
clinic/ 
Referred for evaluation 
of respiratory symptoms 
2 of 13 had impaired FVC and a significant 
postural change. Global respiratory muscle 
weakness in 7 of 13 and diaphragm 
weakness in 4 of 13. 
- yes - - - 15 
Adequ
ate 
Igo, M. 
1993 [29] 
PCS 12 
Unreported/ 
Significant muscle 
impairment – 10 of 12 
were non-ambulatory 
Abnormal VC% in all patients which was 
gradually progressive over time. VC% 
inversely correlated with age. 
- yes - - - - - 
Clague et 
al, 1994 
[30] 
PCS 12 
General neurology 
clinic/ 
Known respiratory 
muscle weakness 
Mean Values: FVC 70.2%, MIP 41.3% 
No difference in perception of respiratory 
effort or ventilatory response to CO2 with 
respiratory muscle weakness 
Yes - - - - 21 Strong 
Ahlström 
et al, 1994 
[5] 
PCS 30 
All known DM1 patients 
in a town in Sweden 
13 of 32 DM1 participants had FVC <70% - yes - - - 21 Strong 
Finnimore 
et al, 1994 
[31] 
PCS 12 
General neurology 
clinic/ 
Variable disease severity 
Mild impairment to all parameters except 
MIP.  Mean FEV1 was 74%, FVC 80%,  
MIP 84% and MEP 32%. 
yes yes yes - - 20 Strong 
Johnson 
et al, 1995 
[32] 
POLS 92 
General neurology 
clinic/ 
Variable disease severity 
Mean FVC 75% and Mean FEV1 76%. 
58% of DM1 participants had mild to severe 
RLD 
yes - - - - 20 Strong 
Ververs et 
al, 1996 
[33] 
PCS 11 
Tertiary respiratory 
clinic/ 
Referred for evaluation 
of daytime sleepiness 
Mean Values: VC 78%, TLC 86%, RV 94%. 
Abnormalities predominantly restrictive 
pattern 
yes yes yes - - 20 Strong 
Zifko et al, 
1996 [8] 
PCS 25 
General neurology 
clinic/ 
Variable disease severity 
Mean FVC was 75% and 15 of 20 participants 
had FVC <80%. Participants with abnormal 
electro-ophysiological parameters had a 
lower FVC% 
yes yes - yes - 21 Strong 
Begin et 
al, 1997 
[7] 
PCS 134 
General neurology 
clinic/ 
Majority of affected 
individuals in the area 
Significantly impaired FVC, worsening with 
severity of muscle weakness. 
Reduced FVC also predicted hypercapnia 
yes yes - yes - 22 Strong 
Abe et al, 
1998 [34] 
PCS 10 
Tertiary respiratory 
centre/Patients referred 
for spirometry 
Restrictive respiratory defect is common in 
this cohort. Correlation between VC and MIP 
indicated respiratory muscle weakness 
involvement in respiratory dysfunction 
Yes - - - - 19 Strong 
Nitz et al, 
1999 [35] 
POLS 36 
General neurology 
clinic/ 
Variable disease severity 
Significant decline in FVC and FEV1 over two 
years of follow up 
- - - Yes - 21 Strong 
Phillips et 
al, 1999 
[36] 
PCS 35 
General neurology 
clinic/  
Variable disease severity 
Significant daytime somnolence in this 
cohort but no correlation with respiratory 
function tests 
- - - - - 21 Strong 
Dahlbom 
et al, 1999 
[37] 
POLS 26 
All known DM1 patients 
in a town in Sweden 
VC declined over the 5 years to varying 
degrees. 
- - - Yes - 21 Strong 
Kinoshita 
et al, 1999 
[38] 
ROCS 40 
Unreported/ 
Variable disease severity 
VC inversely correlated with CTG repeat 
length 
- - - Yes Yes - - 
Marchini 
et al, 2000 
[39] 
ROCS 24 
General neurology 
clinic/ 
Variable disease severity 
Respiratory insufficiency (not specifically 
defined in the article) had no correlation 
with CTG repeat length 
yes yes - - yes 21 Strong 
Oliveri et 
al, 1999 
[40] 
PCS 10 
Unreported/ 
Variable disease severity 
Mean values for VC and PEF were abnormal 
overall.  No relationship between spirometry 
values and P300 latency  
- yes - - - 20 Strong 
López-
Esteban 
et al, 2000 
[41] 
PCS 11 
Tertiary respiratory 
clinic/ 
Referred for evaluation 
of respiratory symptoms 
Moderate to severe ventilatory impairment 
of primarily restrictive type was found in all 
participants 
- - yes - - - - 
Ugalde et 
al, 2001 
[42] 
PCS 10 
General neurology 
clinic/ 
Variable disease severity 
Significantly impaired MEP in this cohort. 
Abdominal accessory muscles recruited at 
lower pressures in DM1 cohort. 
Yes - - - - 21 Strong 
Nugent et 
al, 2002 
[43] 
PCS 13 
Tertiary respiratory 
clinic/ 
All participants 
commencing home non-
invasive ventilation 
All participants had significantly impaired 
spirometry in a restrictive pattern prior to 
commencing NIV.  No significant change in 
spirometry at reassessment was noted, 
suggesting a potential slowing of disease 
progression 
yes yes yes - yes 20 Strong 
Laud et al, 
2006 [44] 
ROCS 29 
Selection of patients 
commencing home NIV 
from a database of NMD 
patients in Sweden 
Most common reason for commencing home 
NIV in DM1 patients was daytime sleepiness, 
followed by daytime hypercapnia on ABG 
- yes - - - 19 Strong 
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Kumar et 
al, 2007 
[45] 
PCS 25 
Tertiary respiratory 
clinic/ 
Referred for evaluation 
of daytime sleepiness 
Sensitivity of FVC <60% in predicting SRDB 
was 67%, specificity 85% 
Concluded daytime spirometry poor 
predictor of SRDB 
yes yes yes - - 21 Strong 
Terzi et al, 
2008 [46] 
POLS 61 
General neurology 
clinic/ 
Variable disease severity 
VC% mean 63.4% at baseline, no significant 
decline in VC% over the year follow up 
yes - - - - 22 Strong 
Nozaki et 
al, 2008 
[47] 
PCS 10 
General neurology 
clinic/ 
Variable disease severity 
No change in respiration associated with 
swallowing 
- - - - - 20 Strong 
Araujo et 
al, 2010 
[6] 
PCS 23 
Unreported/ 
Variable disease severity 
Mean values: FVC 77%, FEV1 77%. 
Loss of expiratory muscle strength 
associated with increasing MIRS score 
yes - - - - - - 
Kiyan et 
al, 2010 
[48] 
ROCS 17 
Tertiary respiratory 
clinic/ 
Referred for routine 
pulmonary workup 
9 of 16 participants had an apparent 
restrictive ventilator pattern. 
Both FVC and FEV1 correlated with daytime 
PaCO2. Mean values: FVC 68%, FEV1 71.4%, 
FEV1/FVC 87.8% 
- yes yes - - 20 Strong 
Kaminsky 
et al, 2011 
[9] 
ROCS 106 
General neurology 
clinic/ 
Variable disease severity 
VC and TLC <80% predicted observed in 60% 
of participants. Restrictive lung disease in 
33% of participants.  VC, TLC and FEV1 was 
related to BMI, CTG repeat length and 
severity of muscle weakness. 
- yes - yes yes 22 Strong 
Pruna et 
al, 2011 
[49] 
ROCS 69 
General neurology 
clinic/ 
Variable disease severity 
More severe muscle weakness was 
associated with higher risk of respiratory 
insufficiency  
- yes - yes yes - - 
Kierkegaa
rd et al, 
2011 [50] 
PCS 70 
General neurology 
clinic/ 
Variable disease severity 
Respiratory dysfunction (impaired FVC or 
FEV1) present in 40% of participants. More 
severe respiratory dysfunction associated 
with MIRS 4 & 5 
- - - Yes - 21 Strong 
Kaminsky 
et al, 2013 
[51] 
ROCS 107 
General neurology 
clinic/ 
Variable disease 
severity, participants 
with pacemakers 
excluded 
40% of participants presented with 
restrictive ventilator pattern. VC and TLC 
both correlated with severity of muscle 
weakness. Mean values: VC 72.6%, TLC 
78.3%.  Presence of restrictive lung disease 
predicted cardiac events. 
- yes - yes yes 22 Strong 
Monteiro 
et al, 2013 
[52] 
ROCS 42 
Tertiary respiratory 
clinic/ 
Referred for evaluation 
for home NIV 
Ventilated participants had lower FVC. FVC 
decreased with age. Mean values: FVC 74%, 
FEV1 77%, MIP 52%, MEP 35% 
yes yes yes - yes 21 Strong 
Bianchi et 
al, 2014 
[53] 
PCS 71 
General neurology 
clinic/ 
Variable disease severity 
FVC was <80% predicted in 9 of the 61 DM1 
participants, with none showing severe 
restrictive pattern 
yes - yes - yes 21 Strong 
Poussel et 
al, 2014 
[54] 
PCS 58 
General neurology 
clinic/ 
All patients ambulatory 
36% of participants presented with a 
restrictive ventilatory pattern, which was 
associated with BMI, CTG repeat length and 
severity of muscle impairment. 
yes yes - yes - 22 Strong 
Fregonezi 
et al, 2015 
[55] 
PCS 25 
General neurology 
clinic/ 
Variable disease severity 
Found a predominantly expiratory muscle 
weakness in the cohort. Mean values: FVC% 
77%, FEV1 75.1%, FEV1/FVC 0.82 
yes - - - - 22 Strong 
Poussel et 
al, 2015 
[10] 
PCS 69 
General neurology 
clinic/ 
Variable disease 
severity, excluding 
patients on home NIV. 
FVC was correlated to MIP and CTG repeat 
length, TLC decline correlated to hypoxaemia 
and hypercapnia.31 of 69 participants 
presented with restrictive ventilatory 
pattern which was associated with higher 
BMI and greater CTG repeat length 
yes yes - yes yes 21 Strong 
Leonardis 
et al, 2015 
[56] 
PCS 25 
General neurology 
clinic/ 
Variable disease severity 
Daytime sleepiness and respiratory 
dysfunction was more prominent in DM1 
participants than in DM2 
Yes Yes - Yes yes 22 Strong 
Carrié et 
al, 2016 
[57] 
PCS 12 
Tertiary respiratory 
clinic/ 
Referred for routine 
pulmonary evaluation 
Spirometry reported as aggregate data of 
multiple NMD (ALS, DMD, DP, POEMS and 
DM1).  Strong correlation between 
ultrasound measured diaphragmatic 
excursion and FVC. 
yes - - - - 20 Strong 
Cho et al, 
2016 [58] 
ROCS 21 
Tertiary respiratory 
clinic/ 
All participants 
commencing home non-
invasive ventilation 
At the point of requiring commencement of 
NIV, DM1 had better respiratory muscle 
function than DMD and ALS participants – 
concluded that this suggested a central 
respiratory drive involvement. Mean values: 
FVC (sit) 39.9%, FVC (supine) 34.7% 
yes - - - - 20 Strong 
Seijger et 
al, 2016 
[59] 
ROCS 105 
Tertiary respiratory 
clinic/ 
Referred for routine 
pulmonary evaluation 
BMI significant predictor of TLC 
independently of respiratory muscle 
weakness. Mean values: VC 83.9%, FEV1 
82.9%, FRC 72.3%, RV 71.1%, TLC 79%, MEP 
55.7%, MIP 65.0% 
- - - yes - 21 Strong 
Evangelist
a et al, 
2017 [60] 
PCS 18 
General neurology 
clinic/ 
Variable disease severity 
Respiratory function showed a 
predominantly restrictive ventilatory 
pattern. 
yes - - - - 22 Strong 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
Respiratory Dysfunction in Myotonic Dystrophy: Systematic Review 31 
 
 
 
O'Donogh
ue et al, 
2017 [61] 
PCS 12 
Tertiary respiratory 
clinic/ 
Patients stable on NIV 
already 
No change in any parameter of spirometry 
after withdrawal of NIV for a month. Mean 
values (baseline): VC 80.67%, FEV1 82.10%, 
TLC 96.13%, RV 113%, FRC 102%, FEV1/VC 
0.81 
- yes yes - - 20 Strong 
Thil et al, 
2017 [62] 
ROCS 80 
General neurology 
clinic/ 
Variable disease severity 
Slow change in RFTs over time compared to 
both normal population and other NMD.  
Faster rate of decline was reported in 
participants who initially had no evidence of 
RLD but developed it during the follow up 
period, compared to participants who 
started with RLD as well as participants who 
never developed RLD. Mean Values: FVC 
(∆/year in % predicted) -0.72, FEV1 (∆ in % 
predicted/year) -1.07, TLC (∆ in % 
predicted/year) -1.15, RV (∆ in % 
predicted/year) -1.49 
- - - - - 21 Strong 
Legend: 
PCS: prospective cross-sectional study, POLS: prospective observational longitudinal study, ROCS: retrospective observational cross-sectional study, RFTs: respiratory function tests, FVC: 
forced vital capacity, VC: vital capacity, FEV1: forced expiratory volume in the first second, TLC: total lung capacity, RV: residual volume, FRC: functional residual capacity, MIP: maximal 
inspiratory pressure, MEP: maximal expiratory pressure, SRDB: sleep-related disordered breathing, PEF: peak expiratory flow, RLD: restrictive lung disease, NIV: non-invasive ventilation at 
home, BMI: body mass index, NMD: neuromuscular disease, DMD: Duchenne’s muscular dystrophy, ALS: amyotrophic lateral sclerosis, DP: demyelinating polyradiculoneuropathy, POEMS: 
polyneuropathy organomegaly endocrinopathy monoclonal gammopathy and skin change. 
Spirometry values reported as % of predicted value unless otherwise stated. 
